Cargando…

Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels

BACKGROUND: Immunotherapy combined with VEGF inhibitor has become the new first-line therapy for advanced or metastatic hepatocellular carcinoma (HCC). However, the biomarkers for response and prognosis stratification of HCC first-line combined immunotherapy have not been clarified. METHODS: Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Jiamin, Li, Yinyin, Wang, Xiaohui, Dong, Zheng, Chen, Yan, Zhang, Rui, Huang, Jiagan, Jin, Xueyuan, Yao, Jianfei, Ge, Aifang, Song, Lele, Lu, Yinying, Zeng, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558640/ https://www.ncbi.nlm.nih.gov/pubmed/34737983 http://dx.doi.org/10.2147/JHC.S326356

Ejemplares similares

Establishment of Criteria for Molecular Differential Diagnosis of MPLC and IPM
por: Wang, Xiaohui, et al.
Publicado: (2021)

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents
por: Yang, Bin, et al.
Publicado: (2019)

Development and Validation of a nomogram for forecasting survival of alcohol related hepatocellular carcinoma patients
por: Yan, Tao, et al.
Publicado: (2022)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells
por: Chen, Yan, et al.
Publicado: (2018)

Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases
por: Wu, Tong, et al.
Publicado: (2021)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
por: Chen, Bowen, et al.
Publicado: (2022)

A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma
por: Zhang, Genhao, et al.
Publicado: (2022)

Prognostic stratification based on m(5)C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Ping, et al.
Publicado: (2022)

Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
por: Chen, Bowen, et al.
Publicado: (2022)

T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy
por: Frank, Meredith L., et al.
Publicado: (2023)

Bringing Light to Transcription: The Optogenetics Repertoire
por: de Mena, Lorena, et al.
Publicado: (2018)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
por: Chang, Xiujuan, et al.
Publicado: (2023)

Regulation of Gamma-Aminobutyric Acid Transaminase Expression and Its Clinical Significance in Hepatocellular Carcinoma
por: Gao, Xiaoqiang, et al.
Publicado: (2022)

A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2023)

A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma
por: Sun, Jianping, et al.
Publicado: (2023)

The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
por: Karpanen, Terhi, et al.
Publicado: (2017)

The temporal behavior of the murine T cell receptor repertoire following Immunotherapy
por: Snir, Tom, et al.
Publicado: (2023)

Age independent survival benefit for patients with small hepatocellular carcinoma undergoing percutaneous cryoablation: A propensity scores matching study
por: Zhang, Huixin, et al.
Publicado: (2023)

Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma
por: Zhang, Li, et al.
Publicado: (2022)

The next age of immunotherapy: optimisation, stratification and therapeutic synergies
por: Halama, Niels
Publicado: (2018)

Title: Multi-Omics and Immune Landscape of Proliferative LncRNA Signatures: Implications for Risk Stratification and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Chi, et al.
Publicado: (2022)

A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing
por: Chen, Xu, et al.
Publicado: (2023)

Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
por: Amon, Lukas, et al.
Publicado: (2020)

Ubiquitin-related molecular classification and risk stratification of hepatocellular carcinoma
por: Yang, Si, et al.
Publicado: (2021)

Immunotherapy of Liver Diseases
por: Feng, Dechun, et al.
Publicado: (2019)

Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma
por: Liang, Fangfang, et al.
Publicado: (2021)

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines
por: Tan, Kar-Tong, et al.
Publicado: (2018)

An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy
por: Lal, Neeraj, et al.
Publicado: (2015)

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy
por: Graf, Jonas, et al.
Publicado: (2017)

Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma
por: Wang, Zifei, et al.
Publicado: (2022)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy
por: Sidhom, John-William, et al.
Publicado: (2022)

RNA-Seq and Immune Repertoire Analysis of Normal and Hepatocellular Carcinoma Relapse After Liver Transplantation
por: Guo, Fansheng, et al.
Publicado: (2023)

m(6)A-mediated modulation coupled with transcriptional regulation shapes long noncoding RNA repertoire of the cGAS-STING signaling
por: Song, Jinyi, et al.
Publicado: (2022)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

The advanced development of molecular targeted therapy for hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2022)

Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma
por: Lei, Jin, et al.
Publicado: (2023)

TFs for TEs: the transcription factor repertoire of mammalian transposable elements
por: Hermant, Clara, et al.
Publicado: (2021)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9lligv8ah5d88mp69ce0s54csu